Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2021 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update

HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
March 30, 2021 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update

Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 Clinical hold lifted on Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in...
March 23, 2021 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

HOUSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
March 04, 2021 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...
January 28, 2021 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the...
December 10, 2020 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment...
December 07, 2020 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has...
November 05, 2020 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update

Strategic focus on clinical GoCAR-T® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year Completed offering of shares of common...
November 03, 2020 20:26 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering

HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing...
October 29, 2020 17:16 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing...